Evrys Bio
Evrys Bio is a biotechnology company developing host-targeted, broad‑spectrum small‑molecule antivirals that modulate human sirtuin enzymes to inhibit replication of diverse RNA and DNA viruses. The company advances discovery‑stage sirtuin modulators through biochemical and cellular assays, transcriptomics, cross‑species animal models and translational biomarker strategies toward IND‑enabling studies and early clinical proof‑of‑concept. Evrys Bio has communicated preclinical results via peer‑reviewed articles and conferences and has received government research awards and SBIR funding to support program development.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Pan‑respiratory broad‑spectrum antiviral program
Preclinical program developing sirtuin‑targeted small molecules active against multiple respiratory viruses including coronaviruses, RSV, adenoviruses and influenza A/B (including drug‑resistant strains).
Antiviral program for opportunistic infections in immunocompromised patients
Small‑molecule sirtuin modulators optimized to prevent or treat opportunistic viral infections in immunosuppressed patients (e.g., cytomegalovirus and other herpes‑ and polyomaviruses).
Medical countermeasure program for emerging/pandemic viruses
Host‑targeted broad‑spectrum antivirals intended as rapid‑response therapeutics and stockpiled countermeasures against emerging viral threats.
Liver infections antiviral program (hepatitis‑focused)
Sirtuin‑targeted small‑molecule program aimed at major causes of viral hepatitis with preclinical data indicating effects on hepatitis B virus replication and cccDNA establishment.
Pan‑respiratory broad‑spectrum antiviral program
Preclinical program developing sirtuin‑targeted small molecules active against multiple respiratory viruses including coronaviruses, RSV, adenoviruses and influenza A/B (including drug‑resistant strains).
Antiviral program for opportunistic infections in immunocompromised patients
Small‑molecule sirtuin modulators optimized to prevent or treat opportunistic viral infections in immunosuppressed patients (e.g., cytomegalovirus and other herpes‑ and polyomaviruses).
Medical countermeasure program for emerging/pandemic viruses
Host‑targeted broad‑spectrum antivirals intended as rapid‑response therapeutics and stockpiled countermeasures against emerging viral threats.
Liver infections antiviral program (hepatitis‑focused)
Sirtuin‑targeted small‑molecule program aimed at major causes of viral hepatitis with preclinical data indicating effects on hepatitis B virus replication and cccDNA establishment.
Expertise Areas
- Host‑targeted antiviral drug discovery
- Medicinal chemistry and lead optimization
- Structure‑based drug design and computational chemistry
- Preclinical virology and in vivo efficacy evaluation
Key Technologies
- Sirtuin‑targeted small‑molecule modulation
- Computer‑aided drug design
- X‑ray crystallography and structural analysis
- Biochemical enzymatic assays
News & Updates
Preclinical and publication announcements describing broad‑spectrum anti‑infective activity of sirtuin‑2 targeting compounds across multiple viral families.
Announcement describing preclinical results where a sirtuin‑2 inhibitor reduced HBV cccDNA establishment and transcriptional activity.
Preclinical presentation summarizing an allosteric SIRT2 modulator with demonstrated antiviral activity in multiple models (presented mid‑2023).
Announcement of a NIH NIAID supplement extending testing of broad‑spectrum antiviral candidates to include SARS‑CoV‑2 in response to emergency research funding.
Award notice for a Phase II Small Business Innovation Research (SBIR) grant supporting development of a single antiviral active against multiple opportunistic infections.
Announcement describing state funding allocations including a grant awarded to the local biotechnology center and an award to the company to support COVID‑19 related antiviral testing.
Preclinical and publication announcements describing broad‑spectrum anti‑infective activity of sirtuin‑2 targeting compounds across multiple viral families.
Announcement describing preclinical results where a sirtuin‑2 inhibitor reduced HBV cccDNA establishment and transcriptional activity.
Preclinical presentation summarizing an allosteric SIRT2 modulator with demonstrated antiviral activity in multiple models (presented mid‑2023).
Announcement of a NIH NIAID supplement extending testing of broad‑spectrum antiviral candidates to include SARS‑CoV‑2 in response to emergency research funding.
Award notice for a Phase II Small Business Innovation Research (SBIR) grant supporting development of a single antiviral active against multiple opportunistic infections.
Announcement describing state funding allocations including a grant awarded to the local biotechnology center and an award to the company to support COVID‑19 related antiviral testing.